Abstract 419P
Background
Tumors of the chest wall are relatively rare. Malignant tumors of the chest wall make up 4% of the structure of cancer and 1-2% of all primary tumors. Malignant tumors of the ribs and sternum made up 13% of the number of patients with bone tumors. The main treatment for chest wall tumors is surgical treatment. Unlike primary, metastatic bone tumors occur 2-4 times more often.
Methods
From 2010 to 2019, in KazIOR provide operations for 78 patients with chest wall tumors, in which 60(76.9%) malignant bone tumors (chondrosarcoma 26(33.3%) and osteogenic sarcoma 34(43.6%), 2(2.6%) metastatic bone lesions, 16(20.5%) soft tissue tumors. The average age was 46.4years, the ratio of men and women 1: 1. 16(20.5%) patients underwent resection of the sternum (manubrium 2(2.6%), body 5(6.4%), xiphoid process 3(3.9%), middle third of the sternum 2(2.6%), the sternum and clavicle 2(2.6%), the xiphoid process of the sternum+costal arch of both sides+diaphragm and peritoneum in 1(1.2%) patient, middle third of the sternum+clavicle+3 ribs 1(1.2%)) and 62(79.5%) resection of the ribs (1 rib 14(17.9%), 2 ribs 12(15.5%), 3 ribs 3(3.9%), 4 ribs 3(3.9%), 5 ribs 1(1.2%), costal arch 1(1.2%), 28(35.9%) patients combined resection of ribs with nearby bones of the chest wall, various structures of the mediastinum and visceral organs.
Results
After resection of 3 ribs or more along the anterolateral surface and total or subtotal resection of the sternum 39(50%) patients underwent reconstructive plastic surgery. In 25(32%) cases used prolene mesh, in 2(2.6%) a displaced skin-fat flap, in 2(2.6%) a thoracodorsal flap (TDL), in 2(2.6%) a greater omentum and in 8(10.2%) combined plasty (prolene mesh+rectoabdominal flap in 2(2.6%) patients, prolene mesh+displaced pectoral flap in 4(5.1%), prolene mesh+TDL in 1(1.2%), prolene mesh + skin-fatty flap in 1(1.2%).
Conclusions
Due to the radical removal of the tumor in combination with the reconstruction of postoperative extensive defects of the chest wall, the quality of life of patients is improved and good functional results are achieved - ease of construction and at the same time the required rigidity of the frame. Despite a significant amount of experimental work research in this area is ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kazakh Reserch Institute of Oncology & Radiology (KazIOR).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
24P - The Pink Vans: Bringing cancer screening closer to home
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
25P - Identification of gene mutations in patients with breast cancer in a region located in the southeast of the European part of Russia
Presenter: Alexander Sultanbaev
Session: e-Poster Display Session
26P - Body mass index and clinical outcomes in Egyptian women with breast cancer: A multi-institutional study
Presenter: Amrou Mamdouh Abdeen Shaaban
Session: e-Poster Display Session
27P - Breast cancer primary site and laterality as predictive factors of prognosis: SEER based analysis for survival
Presenter: Eman Zin Eldin
Session: e-Poster Display Session
28P - Breast cancer care services at Nilai Medical Centre: A Malaysian experience
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
29P - Factors affecting breast self-examination (BSE) behaviour among female high school students in Denpasar City, Bali
Presenter: Cindy Trisina
Session: e-Poster Display Session
30P - Male breast cancer: A rural based peripheral cancer center experience
Presenter: SACHIN KHANDELWAL
Session: e-Poster Display Session
31P - The prognostic value of pre-treatment peripheral neutrophil-lymphocyte-ratio (NLR) and its correlation with mutant p53 expression in Indonesian triple negative breast cancer patients
Presenter: Rosita Purwanto
Session: e-Poster Display Session
32P - Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience
Presenter: Izzet Dogan
Session: e-Poster Display Session
33P - FDG-PET predictivity of pathological axillary nodal status in carcinoma breast-upfront and post-neoadjuvant chemotherapy (NACT) setting
Presenter: Krithikaa Sekar
Session: e-Poster Display Session